AI-enabled pharmaceutical company Algorae Pharmaceuticals (ASX:1AI) has received the comprehensive in silico synergy predictions generated by its AlgoraeOS v2 platform, covering over 500,000 potential combinations of cannabidiol with more than 3,000 approved and investigational drugs across 170 cell lines.
AOS2 outperformed leading global models, including those from Google DeepMind, across all major synergy metrics (ZIP, Bliss, HSA, Loewe), providing confidence-weighted outputs that enable risk-aware prioritisation of high-potential drug combinations.
Preliminary analysis has identified 90 promising CBD–drug candidates for further evaluation, with prioritisation guided by predicted synergy magnitude, uncertainty reduction, and biological generalisability.
Algorae has commenced discussions with the Peter MacCallum Cancer Centre for a second program and independent validation of AOS2 results, building on previous preclinical validation of AOS1.
The company will now progress selected candidates into preclinical assays while continuing to expand its commercial pharmaceutical pipeline.